Buntanetap |
ANVS-405; ANVS-401 |
Phase 3 Clinical |
Raptor Pharmaceutical |
Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia |
Details
|
Gantenerumab |
MAb-31; R-1450; RG-1450; R-04909832 |
Phase 3 Clinical |
Chugai Pharmaceutical Co Ltd |
Alzheimer Disease; Dementia |
Details
|
Valiltramiprosate |
NRM-8499; ALZ-801; BLU-8499 |
Phase 3 Clinical |
Alzheon Inc |
Alzheimer Disease |
Details
|
Solanezumab |
LY-2062430 |
Phase 3 Clinical |
Eli Lilly And Company |
Alzheimer Disease; Dementia; Cognition Disorders |
Details
|
Birtamimab |
NEOD-001 |
Phase 3 Clinical |
Prothena |
Immunoglobulin Light-chain Amyloidosis; Amyloidosis |
Details
|
Remternetug |
LY-3372993 |
Phase 3 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
L-clausenamide |
|
Phase 2 Clinical |
Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd |
Dementia; Cognitive Dysfunction; Memory Disorders |
Details
|
Crenezumab |
MABT-5102-A; RG-7412; R-7412; RO-5490245 |
Phase 2 Clinical |
Ac Immune Sa |
Alzheimer Disease |
Details
|
11C-BF-227 |
11C-BF-227; [11C]BF-227 |
Phase 2 Clinical |
Tohoku University |
Diagnostic agents |
Details
|
Pittsburgh Compound B |
[11C]PIB; [11C]6-OH-BTA-1; 11C-PIB |
Phase 2 Clinical |
The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet |
Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Alzheimer Disease; Alcoholism; Dementia; Parkinson Disease |
Details
|
CT-1812 |
CT-1812; SV-119 |
Phase 2 Clinical |
Cogrx |
Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease; Macular Degeneration |
Details
|
[18F]THK-5105 |
[18F]THK-5105 |
Phase 2 Clinical |
Tohoku University |
Alzheimer Disease |
Details
|
Edonerpic |
T-817 MA |
Phase 2 Clinical |
Toyama Chemical Co Ltd, Fujifilm Group |
Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency |
Details
|
ABvac-40 |
ABvac-40 |
Phase 2 Clinical |
Araclon Biotech Sl |
Alzheimer Disease; Cognitive Dysfunction |
Details
|
PK-051 |
PK051; PK-051 |
Phase 2 Clinical |
PharmaKure Ltd |
Alzheimer Disease; Cognitive Dysfunction |
Details
|
PRI-002 |
RD-2; PRI-002 |
Phase 2 Clinical |
PRInnovation GmbH, Priavoid |
Alzheimer Disease; Cognitive Dysfunction |
Details
|
18F-92 |
18F-92 |
Phase 2 Clinical |
First Affiliated Hospital Of Fujian Medical University |
Alzheimer Disease |
Details
|
SHR-1707 |
SHR-1707 |
Phase 2 Clinical |
Shanghai Hengrui Pharmaceutical Co Ltd |
Alzheimer Disease |
Details
|
[18F]THK-5117 |
[18F]THK-5117 |
Phase 2 Clinical |
Tohoku University |
Alzheimer Disease |
Details
|
AD-35 |
AD-35 |
Phase 2 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Alzheimer Disease |
Details
|
Trontinemab |
RO-7126209; RG-6102 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Alzheimer Disease |
Details
|
APH-1105 |
APH-1105 |
Phase 2 Clinical |
Aphios |
Dementia; Alzheimer Disease |
Details
|
RIV-1061-IR |
RIV-1061; RIV-1061-IR |
Phase 1 Clinical |
Revivo Therapeutics |
Alzheimer Disease; Cognition Disorders |
Details
|
A ß antibody Fab |
|
Phase 1 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
RQ-9 |
AAT-009; RQ-9; RQ-00000009 |
Phase 1 Clinical |
Pfizer Inc |
Dementia |
Details
|
ASN-120290 |
ASN-561; ASN-90; ASN-120290 |
Phase 1 Clinical |
Merck Serono |
Alzheimer Disease; Parkinson Disease |
Details
|
MDR-1339 |
DBT-1339; MDR-1339 |
Phase 1 Clinical |
Medifron |
Alzheimer Disease |
Details
|
AV-1959D |
AV 1959D; AV-1959D |
Phase 1 Clinical |
Institute For Molecular Medicine, University Of California, Flinders University |
Alzheimer Disease |
Details
|
ALZ-101 |
ALZ-101 |
Phase 1 Clinical |
Alzinova AB |
Alzheimer Disease; Dementia |
Details
|
PRX-012 |
PRX-012 |
Phase 1 Clinical |
Prothena |
Alzheimer Disease |
Details
|
PMN-310 |
huPMN-310; PMN-310 |
Phase 1 Clinical |
ProMIS Neurosciences Inc |
Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy |
Details
|
RP-902 |
RP902; RP-902 |
Phase 1 Clinical |
Risen (Suzhou) Pharma Tech Co Ltd |
Alzheimer Disease |
Details
|
ACU-193 |
ACU-193; ACU193 |
Phase 1 Clinical |
Acumen Pharmaceuticals Inc |
Alzheimer Disease |
Details
|
OAB-14 |
OAB-14 |
Phase 1 Clinical |
Shenyang Pharmaceutical University |
Alzheimer Disease |
Details
|
ALN-APP |
|
Phase 1 Clinical |
Sirna Therapeutics Inc |
Cerebral Amyloid Angiopathy; Spinocerebellar Degenerations; Alzheimer Disease; Neurodegenerative Diseases |
Details
|
BEY-2153 |
BEY-2153 |
Phase 1 Clinical |
Beyondbio Inc |
Alzheimer Disease |
Details
|
Abeta42 antibody (Lilly) |
|
Phase 1 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
Anatabine citrate |
RCP-006 |
Clinical |
Rock Creek, Roskamp Institute |
Thyroiditis, Autoimmune; Smoking Cessation; Tobacco Use Disorder; Alzheimer Disease; Inflammation |
Details
|
123I-ABC-577 |
123I-ABC-577 |
Clinical |
Nihon Medi-Physics Co Ltd |
Diagnostic agents |
Details
|
Tarenflurbil spraygel (MIKA Pharma) |
|
Clinical |
Galen Ltd, Mika Pharma Gmbh |
Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic |
Details
|
Procaine Hydrochloride/Vitamin B6/Inositol |
|
|
|
|
Details
|
Inositol/Vitamin B1/Vitamin B2 |
|
|
|
|
Details
|
Buntanetap |
ANVS-405; ANVS-401 |
Phase 3 Clinical |
Raptor Pharmaceutical |
Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia |
Details
|
Gantenerumab |
MAb-31; R-1450; RG-1450; R-04909832 |
Phase 3 Clinical |
Chugai Pharmaceutical Co Ltd |
Alzheimer Disease; Dementia |
Details
|
Valiltramiprosate |
NRM-8499; ALZ-801; BLU-8499 |
Phase 3 Clinical |
Alzheon Inc |
Alzheimer Disease |
Details
|
Solanezumab |
LY-2062430 |
Phase 3 Clinical |
Eli Lilly And Company |
Alzheimer Disease; Dementia; Cognition Disorders |
Details
|
Birtamimab |
NEOD-001 |
Phase 3 Clinical |
Prothena |
Immunoglobulin Light-chain Amyloidosis; Amyloidosis |
Details
|
Remternetug |
LY-3372993 |
Phase 3 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
L-clausenamide |
|
Phase 2 Clinical |
Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd |
Dementia; Cognitive Dysfunction; Memory Disorders |
Details
|
Crenezumab |
MABT-5102-A; RG-7412; R-7412; RO-5490245 |
Phase 2 Clinical |
Ac Immune Sa |
Alzheimer Disease |
Details
|
11C-BF-227 |
11C-BF-227; [11C]BF-227 |
Phase 2 Clinical |
Tohoku University |
Diagnostic agents |
Details
|
Pittsburgh Compound B |
[11C]PIB; [11C]6-OH-BTA-1; 11C-PIB |
Phase 2 Clinical |
The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet |
Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Alzheimer Disease; Alcoholism; Dementia; Parkinson Disease |
Details
|
CT-1812 |
CT-1812; SV-119 |
Phase 2 Clinical |
Cogrx |
Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease; Macular Degeneration |
Details
|
[18F]THK-5105 |
[18F]THK-5105 |
Phase 2 Clinical |
Tohoku University |
Alzheimer Disease |
Details
|
Edonerpic |
T-817 MA |
Phase 2 Clinical |
Toyama Chemical Co Ltd, Fujifilm Group |
Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency |
Details
|
ABvac-40 |
ABvac-40 |
Phase 2 Clinical |
Araclon Biotech Sl |
Alzheimer Disease; Cognitive Dysfunction |
Details
|
PK-051 |
PK051; PK-051 |
Phase 2 Clinical |
PharmaKure Ltd |
Alzheimer Disease; Cognitive Dysfunction |
Details
|
PRI-002 |
RD-2; PRI-002 |
Phase 2 Clinical |
PRInnovation GmbH, Priavoid |
Alzheimer Disease; Cognitive Dysfunction |
Details
|
18F-92 |
18F-92 |
Phase 2 Clinical |
First Affiliated Hospital Of Fujian Medical University |
Alzheimer Disease |
Details
|
SHR-1707 |
SHR-1707 |
Phase 2 Clinical |
Shanghai Hengrui Pharmaceutical Co Ltd |
Alzheimer Disease |
Details
|
[18F]THK-5117 |
[18F]THK-5117 |
Phase 2 Clinical |
Tohoku University |
Alzheimer Disease |
Details
|
AD-35 |
AD-35 |
Phase 2 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Alzheimer Disease |
Details
|
Trontinemab |
RO-7126209; RG-6102 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Alzheimer Disease |
Details
|
APH-1105 |
APH-1105 |
Phase 2 Clinical |
Aphios |
Dementia; Alzheimer Disease |
Details
|
RIV-1061-IR |
RIV-1061; RIV-1061-IR |
Phase 1 Clinical |
Revivo Therapeutics |
Alzheimer Disease; Cognition Disorders |
Details
|
A ß antibody Fab |
|
Phase 1 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
RQ-9 |
AAT-009; RQ-9; RQ-00000009 |
Phase 1 Clinical |
Pfizer Inc |
Dementia |
Details
|
ASN-120290 |
ASN-561; ASN-90; ASN-120290 |
Phase 1 Clinical |
Merck Serono |
Alzheimer Disease; Parkinson Disease |
Details
|
MDR-1339 |
DBT-1339; MDR-1339 |
Phase 1 Clinical |
Medifron |
Alzheimer Disease |
Details
|
AV-1959D |
AV 1959D; AV-1959D |
Phase 1 Clinical |
Institute For Molecular Medicine, University Of California, Flinders University |
Alzheimer Disease |
Details
|
ALZ-101 |
ALZ-101 |
Phase 1 Clinical |
Alzinova AB |
Alzheimer Disease; Dementia |
Details
|
PRX-012 |
PRX-012 |
Phase 1 Clinical |
Prothena |
Alzheimer Disease |
Details
|
PMN-310 |
huPMN-310; PMN-310 |
Phase 1 Clinical |
ProMIS Neurosciences Inc |
Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy |
Details
|
RP-902 |
RP902; RP-902 |
Phase 1 Clinical |
Risen (Suzhou) Pharma Tech Co Ltd |
Alzheimer Disease |
Details
|
ACU-193 |
ACU-193; ACU193 |
Phase 1 Clinical |
Acumen Pharmaceuticals Inc |
Alzheimer Disease |
Details
|
OAB-14 |
OAB-14 |
Phase 1 Clinical |
Shenyang Pharmaceutical University |
Alzheimer Disease |
Details
|
ALN-APP |
|
Phase 1 Clinical |
Sirna Therapeutics Inc |
Cerebral Amyloid Angiopathy; Spinocerebellar Degenerations; Alzheimer Disease; Neurodegenerative Diseases |
Details
|
BEY-2153 |
BEY-2153 |
Phase 1 Clinical |
Beyondbio Inc |
Alzheimer Disease |
Details
|
Abeta42 antibody (Lilly) |
|
Phase 1 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
Anatabine citrate |
RCP-006 |
Clinical |
Rock Creek, Roskamp Institute |
Thyroiditis, Autoimmune; Smoking Cessation; Tobacco Use Disorder; Alzheimer Disease; Inflammation |
Details
|
123I-ABC-577 |
123I-ABC-577 |
Clinical |
Nihon Medi-Physics Co Ltd |
Diagnostic agents |
Details
|
Tarenflurbil spraygel (MIKA Pharma) |
|
Clinical |
Galen Ltd, Mika Pharma Gmbh |
Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic |
Details
|
Procaine Hydrochloride/Vitamin B6/Inositol |
|
|
|
|
Details
|
Inositol/Vitamin B1/Vitamin B2 |
|
|
|
|
Details
|